Novartis Ag

Other

Sandoz Gmbh

Sylvain Cottens

Werner Breitenstein

Richard Sedrani

Rainer Albert

Claus Ehrhardt

Peter Von Matt

Nigel Graham Cooke

Gerhard Zenke

Jean-Pierre Evenou

Wilfried Bauer

Roland M Wenger

Jürgen Wagner

Robert Paul Hof

Barbara Haeberlin

Nils Ostermann

Oliver Simic

Ulrich Hommel

Josef Gottfried Meingassner

Klaus Hinterding

Jacky Vonderscher

Juergen Klaus Maibaum

Edwige Liliane Jeanne Lorthiois

Holger Sellner

J&ouml;rg Kallen

Rolf Baenteli

Gabriele Weitz-Schmidt

Volker Brinkmann

Christos Papageorgiou

Gabriele Weitz Schmidt

Dieter Geyl

Thomas Baumruker

Eva Erika Prieschl-Strassmayr

Fran&ccedil;ois Nuninger

J&uuml;rgen Wagner

Edgar Jacoby

Indolylmaleimide derivatives comprising either a substituted phenyl, naphthyl, tetrahydronaphthyl, quinazolinyl, quinolyl, isoquinolyl or pyrimidinyl residue have interesting pharmaceutical properties, e.g. in the treatment and/or prevention of T-cell mediated acute or chronic inflammatory diseases or disorders, autoimmune diseases, graft rejection or cancer.

Indolylmaleimide derivatives

Compounds of formula I wherein m, R, Rand Rto Rare as defined in the specification, m, is 1, 2 or 3 and X is O or a direct bond, and the corresponding unphosporylated compounds have interesting properties, e.g. immunosuppressive properties.

2-amino-propanol derivatives

This invention provides a microemulsion pre-concentrate comprising a difficultly soluble active agent and a carrier medium comprising 1) a hydrophilic phase which comprises dimethylisosorbide and/or a lower alkyl alkanoic ester, 2) a lipophilic phase, and 3) a surfactant. The active agent may be a cyclosporin or a macrolide. In another aspect, this invention provides a pharmaceutical composition for enteral or parenteral administration comprising a macrolide and an acid.

Pharmaceutical compositions

Mevinolin derivatives wherein the lactone ring is modified have interesting pharmaceutical properties, particularly in preventing or treating disorders or diseases mediated by LFA-1/ICAM-1 interactions.

Melvinolin derivatives

Mevinolin compounds for use in the treatment or prevention of autoimmune diseases, inflammation, ischemia/reperfusion injury and graft rejection. Such compounds bind to the LFA-1 I-domain and thereby inhibit LFA-1/ICAM-1 or LFA-1/ICAM-3 interactions.

Lymphocyte function antigen-1 antagonists

Use for 1,3-propanediol derivatives

Novel derivatives of rapamycin, particularly 9-deoxo-rapamycins, 26-dihydro-rapamycins, and 40-O-substituted and 28,40-O,O-disubstituted rapamycins. are found to have pharmaceutical utility, particularly as immunosuppressants.

O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants

Use of a compound of formula (I) wherein R,is an optionally substituted straight- or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and each of R,, R,, R,and R,, independently, is H or lower alkyl, in free form or in pharmaceutically acceptable salt form, in the prevention or treatment of chronic rejection in a recipient of organ or tissue allo- or xenotransplant, or of acute rejection in a xenograft transplant recipient.

Rapamycin derivatives are disclosed of the formula:

Rapamycin derivatives

O-alkylated rapamycin derivatives and their use, particularly as

Halogenoalkylphenyl-alcohols, ketones and their hydrates of formula I, ##STR1## wherein R.sub.1 to R.sub.8 are as defined in the description, are useful as acetylcholinesterase inhibitors.

Halogenoalkylphenyl-alcohols, ketones and hydrates thereof

Growing community of inventors

Witterswil, Switzerland

Sylvain Cottens